Increasing Efficacy of Antibody Tests Propelling Growth of Global Immunoassay Market Amidst COVID-19 Pandemic

The growth of the global immunoassay market is being propelled by the drive to increase the efficacy of antibody tests amidst the COVID-19 pandemic, led further by the growing use of immunoassay methods in diagnosis of various autoimmune diseases.

These are the latest findings of TMR Research (San Francisco, CA, USA), a provider of customized market research and consulting services.

Immunoassay methods are used to quantify the concentration of analyte of interest. Their use in high-throughput screening has risen substantially, endowing some sizable revenues to market players. The methods are based on the specificity and selectivity of antibody reagents generated, which take into account assay critical success factors. Use of immunoassays has made some remarkable penetration in automated clinical chemistry laboratory applications. Their use in accurate diagnosis of autoimmune diseases is noticeable and industry players have earned some substantial revenues from the use of these in hospitals settings. Some of the popular techniques in the immunoassay market are Chemiluminescent immunoassay (CLIA), RIA, Elisa (enzyme-linked immunosorbent assay), and rapid test.

The drive toward increasing the efficacy of antibody tests is a key factor propelling developments in the immunoassay market. Automation in clinical lab processes and advent of new analytical platforms have set the tone for innovations in the market. The growing use of immunoassay methods in diagnosis of various autoimmune diseases is a key trend spurring revenue generation in the immunoassay market. Some of the diseases where immunoassay has proved to be helpful are systemic lupus erythematosus (SLE), rheumatoid arthritis, systemic sclerosis, antiphospholipid syndrome, and Sjögren’s syndrome. The evolution of the market has been pivoting on immunoassay labeling technology. For instance, Radioimmunoassay (RIA) has undergone vast change over the past few decades. Strides made in the autoantibody detection have greatly advanced growth possibilities in the immunoassay market.

Policy makers and healthcare systems trying to control rising cases of COVID-19 pandemic and frame strategies to understand how the impact of the disease can be mitigated have high hopes on developments in immunoassay. SARS-CoV-2 seroprevalence currently attracts huge interest among economies suffering from the fallout of the recent outbreaks. Seroprevalence can be achieved by successful serological testing of large array of antibodies to SARS-CoV-2. Novel assays are needed to ascertain whether individuals have developed adequate immunity after vaccination and what is the duration of antibody responses.

Recently, high-throughput SARS-CoV-2 multiplex microsphere immunoassay (MMIA) has demonstrated potential and is attracting the attention of epidemiologists in estimating transmission dynamics. The immunoassay has been tested in first responders (FRs) in the US. The drive for effective serosurveillance stems from the intense need for developing effective health strategies for public health management of various infectious disease outbreaks in future. The trend is driving revenue generation for the players in the immunoassay market.

Geographically, North America has been a highly lucrative market and has made some remarkable advances in developing and validating new immunoassays, such as Chemiluminescent immunoassay technology. The US has been an early adopter of automated technologies. The region as a whole has seen sizable spending on advancing autoimmunology laboratory organization in its key economies, thereby cementing its growth prospects in the global immunoassay market. The commercialization of cutting-edge new analytical platforms is likely to sustain the growth momentum of the North American market in the next few years as well.


Related Links:
TMR Research